Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, announced it has launched Magnesium Sulfate in Water for Injection in the United States as approved by the U.S.
Food and Drug Administration. Magnesium Sulfate in Water for Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. When used judiciously, it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose.
Avenacy's Magnesium Sulfate in Water for Injection is available in Ready-to-Use Premix IV bags in multiple formulations: 2g/50mL (40mg/mL), 4g/100mL (40mg/mL), and 4g/50mL (80mg/mL). In line with Avenacy’s mission to champion patient safety and streamline patient care, Magnesium Sulfate in Water for Injection will feature the Company’s highly differentiated packaging and labeling to support accurate medication selection. Additionally, the Ready-to-Use presentation is expected to help reduce dosing inaccuracies, enhance patient safety, and streamline inventory.
“As a vital product for healthcare providers, Magnesium Sulfate represents a large market opportunity for Avenacy, and we are excited to deliver this ready-to-use product to hospitals all over the country as a means to improve patient care,” said Jeff Yordon, Co-Founder and CEO of Avenacy. “Since launching seven months ago, we have seen very encouraging early traction of Avenacy’s products in the market, and we are proud to be launching our eighth product as we continue to scale up our business in order to meet demand for our injectable medications.”
Avenacy will partner with Milla Pharmaceuticals Inc., (“Milla Pharmaceuticals”), the U.S. subsidiary of global generic and pharmacy service player A.forall (“A.forall”), to begin shipping Magnesium Sulfate in Water for Injection to wholesale partners this week. Milla Pharmaceuticals is part of Avenacy’s global network of development and contract manufacturing partners that have undergone successful FDA inspections based on cGMP standards.
“We're excited to work with Avenacy to introduce Magnesium Sulfate in Water for Injection to the market,” said Erik Lazarich, President of A.forall’s U.S. Operations, “Delivering this ready-to-use product to hospitals nationwide is a key step in improving patient care and advancing our mission of making affordable medicines available to all.”
For more information, please visit http://www.avenacy.com/.
